Forest Labs on hold by Jefferies

Forest Laboratories, Inc. was rated at hold with a $44 price target by Jefferies & Co., Inc. analyst David Windley. Jefferies expects Forest to beat consensus revenue forecast of $768 million, driven in large part by Lexapro. The analyst is forecasting $787 million in revenues, earnings per share of $0.38 for the March quarter, and 2007 earnings per share up 13 cents to $2.59. Shares of the New York pharmaceutical company were down 10 cents, or 0.23%, at $42.88 on volume of 1,008,700 shares versus the three-month running average of 2,307,070 shares. (NYSE: FRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.